New ALS drug trial aims to slow Disease's deadly march
NCT ID NCT06453668
First seen Jan 16, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This early-stage study tests whether siplizumab is safe for people recently diagnosed with ALS (Lou Gehrig's disease). About 48 adults will receive the drug and be monitored for 52 weeks. The goal is to check for side effects and see how the drug behaves in the body, not yet to prove it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Skåne University Hospital Malmö
RECRUITINGMalmö, 205 02, Sweden
Contact
-
Studieenheten Akademiskt Specialistcentrum
RECRUITINGStockholm, 171 77, Sweden
Contact
-
Umeå University Hospital
RECRUITINGUmeå, 901 85, Sweden
Contact
Conditions
Explore the condition pages connected to this study.